نتائج البحث

Chimeric Antigen Receptor T-cells for the Treatment of AML Expressing CLL-1 Antigen

• Authors : The Methodist Hospital Research Institute; Center for Cell and Gene Therapy, Baylor College of Medicine; LaQuisa Hill, Assistant Professor

• Source: Chimeric Antigen Receptor T-cells for the

تفاصيل العنوان

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

• Authors : Hebei Taihe Chunyu Biotechnology Co., Ltd

• Source: To Observe the Long-term Efficacy and Safety of Dual-target Chimeric Antigen Receptor

تفاصيل العنوان

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

• Source: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody

تفاصيل العنوان

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

• Source: A Phase I Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor

تفاصيل العنوان

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

• Authors : Jing Pan, Director of Dept of Hemato-Oncology and Immunotherapy

• Source: A Single-Center, Open-Label, Non-Randomized, Single-Arm Clinical Study on the Treatment of Refractory Autoimmune Diseases With CD19-CAR T

تفاصيل العنوان

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies (PRODIGY)

• Source: Pilot Study of Anti-CD19 Chimeric Antigen Receptor T

تفاصيل العنوان

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

• Authors : Jing Pan, Director of Dept of Hemato-Oncology and Immunotherapy

• Source: Open-Label, Non-Randomized, Single-Arm, Phase 1/2 Study of Anti-CD19 Chimeric Antigen Receptor

تفاصيل العنوان

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

• Source: Phase I Clinical Trial of Autologous B7-H3 Chimeric Antigen Receptor T

تفاصيل العنوان

B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme

• Authors : California Institute for Regenerative Medicine (CIRM); Crystal Mackall, MD, Professor of Pediatrics and of Medicine Pediatrics - Hematology/Oncology

• Source: Phase I Clinical Trial of Locoregionally (LR) Delivered Autologous B7-H3 Chimeric Antigen Receptor

تفاصيل العنوان

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

• Authors : Benjamin Tomlinson, Principal Investigator

• Source: Phase I Clinical Trial of Human AntiCD19 Chimeric Antigen Receptor T

تفاصيل العنوان